JP2023076632A5 - - Google Patents

Download PDF

Info

Publication number
JP2023076632A5
JP2023076632A5 JP2023061284A JP2023061284A JP2023076632A5 JP 2023076632 A5 JP2023076632 A5 JP 2023076632A5 JP 2023061284 A JP2023061284 A JP 2023061284A JP 2023061284 A JP2023061284 A JP 2023061284A JP 2023076632 A5 JP2023076632 A5 JP 2023076632A5
Authority
JP
Japan
Prior art keywords
fibrosis
amino
therapeutic agent
agent according
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023061284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023076632A (ja
JP7498827B2 (ja
Filing date
Publication date
Priority claimed from JP2017525457A external-priority patent/JP6974167B2/ja
Application filed filed Critical
Publication of JP2023076632A publication Critical patent/JP2023076632A/ja
Publication of JP2023076632A5 publication Critical patent/JP2023076632A5/ja
Application granted granted Critical
Publication of JP7498827B2 publication Critical patent/JP7498827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023061284A 2015-06-25 2023-04-05 線維症治療剤 Active JP7498827B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25
JP2015127788 2015-06-25
JP2017525457A JP6974167B2 (ja) 2015-06-25 2016-06-24 線維症治療剤
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤
JP2021180108A JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021180108A Division JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤

Publications (3)

Publication Number Publication Date
JP2023076632A JP2023076632A (ja) 2023-06-01
JP2023076632A5 true JP2023076632A5 (https=) 2023-07-07
JP7498827B2 JP7498827B2 (ja) 2024-06-12

Family

ID=57585165

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017525457A Active JP6974167B2 (ja) 2015-06-25 2016-06-24 線維症治療剤
JP2021180108A Active JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤
JP2023061284A Active JP7498827B2 (ja) 2015-06-25 2023-04-05 線維症治療剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017525457A Active JP6974167B2 (ja) 2015-06-25 2016-06-24 線維症治療剤
JP2021180108A Active JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤

Country Status (20)

Country Link
US (4) US10449189B2 (https=)
EP (2) EP3973962A1 (https=)
JP (3) JP6974167B2 (https=)
KR (1) KR102647942B1 (https=)
CN (2) CN112716952A (https=)
AU (1) AU2016284531B2 (https=)
BR (1) BR112017028137B1 (https=)
CA (1) CA2990791A1 (https=)
DK (1) DK3315131T3 (https=)
ES (1) ES2928684T3 (https=)
HU (1) HUE060732T2 (https=)
MA (1) MA42266A (https=)
MX (2) MX381792B (https=)
MY (1) MY191219A (https=)
PH (1) PH12017502322B1 (https=)
PL (1) PL3315131T3 (https=)
PT (1) PT3315131T (https=)
RU (1) RU2729630C2 (https=)
SG (2) SG11201709260TA (https=)
WO (1) WO2016208744A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
MA42266A (fr) * 2015-06-25 2018-05-02 Taiho Pharmaceutical Co Ltd Agent thérapeutique contre la fibrose
HUE068810T2 (hu) 2017-02-15 2025-01-28 Taiho Pharmaceutical Co Ltd Gyógyászati készítmény
MA50251A (fr) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co Ltd Agent antitumoral et potentialisateur d'effet antitumoral
US20210369739A1 (en) 2018-09-18 2021-12-02 Taiho Pharmaceutical Co., Ltd. Combination therapy of acylthiourea compound and abiraterone
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69939586D1 (de) 1998-04-28 2008-10-30 Toshikazu Nakamura Inhibitoren für die gefässneubildung
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
KR101414931B1 (ko) * 2008-04-10 2014-07-04 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물 또는 그 염 및 그 용도
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA025304B1 (ru) * 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
MA42266A (fr) * 2015-06-25 2018-05-02 Taiho Pharmaceutical Co Ltd Agent thérapeutique contre la fibrose

Similar Documents

Publication Publication Date Title
JP2023076632A5 (https=)
JP5557169B2 (ja) ナテグリニド含有製剤
RU2003127750A (ru) 4-фтор-n-индан-2-илбензамид и его применение в качестве фармацевтического агента
JP5769763B2 (ja) 治療用組成物およびその使用
JP2019059760A5 (https=)
JP2002519318A5 (https=)
JP2007511487A5 (https=)
RU2008148547A (ru) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
HU202102B (en) Process for producing oral pharmaceutical compositions with controlled release of the active components
CA2671470A1 (en) Powder formulation for valganciclovir
JP2023057082A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP2002528502A5 (https=)
JP2009517411A5 (https=)
JPWO2023054732A5 (https=)
JP2019510834A5 (https=)
JP2004532828A5 (https=)
JP2005511724A (ja) 鼻炎を処置するためのh1アンタゴニストおよび安全なステロイドの使用
JPWO2021110805A5 (https=)
JP2006524190A5 (https=)
JPH10513186A (ja) Hivプロテアーゼ阻害剤インジナビル及び逆転写酵素阻害剤3tcを必要に応じてazt、ddi、又はddcと共に用いるhiv感染の組合せ治療
JP2007524699A5 (https=)
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
EA199900226A1 (ru) Фармацевтические композиции для лечения вирусных заболеваний
RU2007143087A (ru) Композиция с модифицированным высвобождением минимум одной формы венлафаксина
CN104780921A (zh) Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合